Metformin administration attenuates dipeptidyl peptidase-4 inhibitor-induced increases in Krebs von den Lungen-6 (KL-6) levels

J Diabetes. 2019 Jan;11(1):95-96. doi: 10.1111/1753-0407.12852. Epub 2018 Oct 7.

Authors

Junichi Okada^{1

2}, Eijiro Yamada², Yawara Niijima¹, Shuichi Okada^{1

2}, Masanobu Yamada²

Affiliations

¹ Kan-etsu Chuo Hospital, Gunma, Japan.
² Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma, Japan.

PMID: 30191664
DOI: 10.1111/1753-0407.12852

No abstract available

Publication types

Letter

MeSH terms

Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / metabolism
Dipeptidyl-Peptidase IV Inhibitors / administration & dosage
Dipeptidyl-Peptidase IV Inhibitors / adverse effects*
Gene Expression Regulation / drug effects*
Humans
Hypoglycemic Agents / therapeutic use*
Lung Diseases, Interstitial / chemically induced
Lung Diseases, Interstitial / diagnosis*
Lung Diseases, Interstitial / metabolism
Metformin / therapeutic use*
Mucin-1 / metabolism*

Substances

Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents
MUC1 protein, human
Mucin-1
Metformin